Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.

about

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.

P2860

Q38546981-7B2E16DC-E278-42DA-80FF-F397B22DFBCD

P2860

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.

Item

http://www.wikidata.org/entity/Q36196649

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Potential role of linagliptin ...... patients with type 2 diabetes.

@ast

Potential role of linagliptin ...... patients with type 2 diabetes.

@en

type

Item

label

Potential role of linagliptin ...... patients with type 2 diabetes.

@ast

Potential role of linagliptin ...... patients with type 2 diabetes.

@en

prefLabel

Potential role of linagliptin ...... patients with type 2 diabetes.

@ast

Potential role of linagliptin ...... patients with type 2 diabetes.

@en

P1476

Potential role of linagliptin ...... patients with type 2 diabetes.

@en

P2093

Jørgen Rungby

http://www.w3.org/2001/XMLSchema#string

Lene Hoimark

http://www.w3.org/2001/XMLSchema#string

Torben Laursen

http://www.w3.org/2001/XMLSchema#string

P2860

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

DPP-4 inhibitors and lipids: systematic review and meta-analysis.

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.

Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.

Pharmacokinetics of linagliptin in subjects with hepatic impairment

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.

Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.

P304

295-302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DMSO.S16288

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230804963

http://www.w3.org/2001/XMLSchema#string

P698

22952411

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3430084

http://www.w3.org/2001/XMLSchema#string

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.

about

P2860

P2860

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932